Dallas, Texas (PRWEB) December 08, 2013
The Global Biosimulation market is witnessing increasing collaborations and partnerships between vendors. Such collaborations are aiding innovation in the market. For instance, Genedata is collaborating with Insilico Biotechnology AG, which is a Germany-based provider of software and solutions for the simulation of living cells, to support life science companies in improving and enhancing their biotechnological production methods. Additionally, a number of vendors in the Global Biosimulation market (http://www.reportsnreports.com/reports/271328-global-biosimulation-market-2014-2018.html) collaborate with pharmaceutical companies. For instance, in May 2013, Accelrys Inc., a US-based provider of scientific enterprise software, signed a three-year agreement with Pfizer Inc., a pharmaceutical company, for the use of its products such as, modeling and simulation software, by Pfizer’s researchers worldwide.
Analysts forecast the Global Biosimulation market to grow at a CAGR of 18.31 percent over the period 2013-2018. According to the report, one of the most important drivers is the reduction in the drug discovery and development costs of pharmaceutical companies as a result of deploying biosimulation software solutions during the R&D process. Since such software brings about an understanding of clinical outcomes before human trials, their use adds immense value to pharmaceutical companies involved in the R&D of drugs, and helps companies reduce costs.
Further, the report states that one of the major challenges in the market is the high R&D costs associated with the development of biosimulation software. Several biosimulation models offer a virtual patient population to aid the development and testing of drugs, but these models are constructed using a large amount of data, which increases costs.
Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=271328.
The report recognizes the following companies as the key players in the Global Biosimulation Market: Advanced Chemistry Development Inc., Accelrys Inc., Archimedes Inc., Certara L.P., Compugen Inc., Entelos Inc., Genedata AG, Insilico Biotechnology AG, LeadInvent Technologies Pvt. Ltd., Rhenovia Pharma SAS, Schrodinger LLC, and Simulations Plus Inc.
Other vendors mentioned in the report are Advanced Chemistry Development Inc., Archimedes Inc., Bayer Technology Services, Biomed Simulation Inc., Chemical Computing Group Inc., Compugen Ltd., Entelos Inc., Genedata AG, Immunetrix Inc., InhibOx Ltd., INOSIM Software GmbH, In Silico Biosciences Inc., Insilico Biotechnology AG, LeadInvent Technologies Pvt. Ltd., Leadscope Inc., Molecular Knowledge Systems Inc., Nimbus Discovery Llc, OpenEye Scientific Software Inc., Optimata Inc., Physiomics Plc, Rhenovia Pharma SAS, Synergix Ltd., and Vascular Sciences.
Get Discount @ http://www.reportsnreports.com/contacts/discount.aspx?name=271328.
Key questions answered in this report: